Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745549 | 0.81 | LMNA (0.48) | HSD17B10KDM4EATMMAPTALDH1A1 | |
| SCHEMBL29199432 | 0.78 | HSD17B10 (0.48) | HSD17B10GFERMAPK1KDM4EGLA | |
| SCHEMBL20745626 | 0.69 | LMNA (0.47) | HSD17B10KDM4EGLAATMMAPT | |
| SCHEMBL21462093 | 0.68 | ABCB11 (0.49) | HSD17B10GFERMAPK1KDM4EGLA | |
| SCHEMBL20745577 | 0.68 | ALDH1A1 (0.46) | HSD17B10KDM4EATMMAPTALDH1A1 | |
| SCHEMBL31302523 | 0.67 | GPR35 (0.43) | KDM4EGLAGPR35MAPTALDH1A1 | |
| SCHEMBL20745836 | 0.66 | LMNA (0.43) | HSD17B10KDM4EALDH1A1GAARAB9A | |
| SCHEMBL14557301 | 0.65 | KEAP1 (0.58) | GFERKDM4EMAPTALDH1A1HPGD | |
| SCHEMBL31421842 | 0.65 | KEAP1 (0.58) | GFERKDM4EMAPTALDH1A1HPGD | |
| SCHEMBL13314716 | 0.64 | MEN1 (0.36) | HSD17B10KDM4EMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11957680-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| EP-3668881-B1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3668512-B1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220395503-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | disclosed |
| EP-4026838-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | Agios Pharmaceuticals, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3668513-B1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-11040036-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210077490-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2021-03-18 | — | — | US | disclosed |
| EP-3668881-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | Agios Pharmaceuticals, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668513-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | Agios Pharmaceuticals, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668512-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | Agios Pharmaceuticals, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019035865-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035864-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035863-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395503-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | HSD17B10 739/4885GFER 4193/4885MAPK1 502/4885 |
| US-20210077490-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | HSD17B10 1064/4885GFER 4004/4885MAPK1 740/4885 |
| US-11957680-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | HSD17B10 739/4885GFER 4193/4885MAPK1 502/4885 |
| US-11040036-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | HSD17B10 1064/4885GFER 4004/4885MAPK1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.